1Patricia Aikins Murphy is Assistant Professor of Nursing in the Nurse-Midwifery Education Program at Columbia University. She is a graduate of that program, and holds a doctorate in epidemiology from the Columbia University School of Public Health. Her research interests include clinical preventive services in women's health.
USE OF ORAL METRONIDAZOLE IN PREGNANCY: Risks, Benefits, and Practice Guidelines
Article first published online: 6 JAN 2011
1994 American College of Nurse Midwives
Journal of Nurse-Midwifery
Volume 39, Issue 4, pages 214–220, July-August 1994
How to Cite
Murphy, P. A. and Jones, E. (1994), USE OF ORAL METRONIDAZOLE IN PREGNANCY: Risks, Benefits, and Practice Guidelines. Journal of Nurse-Midwifery, 39: 214–220. doi: 10.1016/0091-2182(94)90027-2
- Issue published online: 6 JAN 2011
- Article first published online: 6 JAN 2011
Metronidazole is the recommended treatment for trichomoniasis and bacterial vaginosis in nonpregnant women. Reluctance to use this drug in pregnancy is related to concerns about possible adverse effects on the fetus. However, recent literature suggests associations between these infections during pregnancy and risk of preterm delivery; if such associations are causal and preterm birth is shown to be prevented by effective treatment, the risk-benefit equation may be altered. This article reviews the literature on the carcinogenic and teratogenic potential of metronidazole and discusses the evidence that associates trichomoniasis and bacterial vaginosis with perinatal outcomes. Current practice recommendations are summarized.